Proteologics proteologics.com


Public lists: Pharma Startups (4732)

PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing technology and knowledge of the ubiquitin system.

PROTEOLOGICS develops a class of drugs for viral and other ubiquitin-mediated diseases utilizing technology and knowledge of the ubiquitin system.

Company (Alive / Active)

Phone:

Fax:

40 Ramland Road South
Suite 10
Orangeburg, 10962
New York, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Proteologics $17M Oct 16, 2001
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Proteologics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 4 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Panacos Pharmaceuticals

Watertown, Massachusetts, United States
Alive / ActivePanacos is developing anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Per the company, Panacos' proprietary discovery technologies are designed to combat resistance by focusing on novel targets in the virus life cycle, including virus maturation and virus fusion.Login to see details

Peptimmune

Cambridge, Massachusetts, United States
Dead / InactivePeptimmune develops drugs for the treatment of various autoimmune diseases.Login to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Pyrimidine derivatives as posh and posh-ap inhibitors Nov 07, 2007 Oct 09, 2012 Patent
Ubiquitin ligase assays and related reagents Oct 22, 2012 Application